SkinBioTherapeutics (LON:SBTX) Shares Down 10.3% – Here’s What Happened

Shares of SkinBioTherapeutics plc (LON:SBTX) traded down 10.3% during trading on Tuesday . The company traded as low as GBX 18.83 and last traded at GBX 18.83. 949,555 shares traded hands during trading, a decline of 34% from the average session volume of 1,447,515 shares. The stock had previously closed at GBX 21.

SkinBioTherapeutics Stock Performance

The firm’s 50 day moving average price is GBX 15.70 and its 200-day moving average price is GBX 15.67. The firm has a market cap of £49.09 million, a price-to-earnings ratio of -61.19 and a beta of 2.01. The company has a debt-to-equity ratio of 27.57, a current ratio of 0.93 and a quick ratio of 10.01.

SkinBioTherapeutics (LON:SBTX) last released its earnings results on Monday, December 8th. The company reported GBX (0.31) EPS for the quarter. SkinBioTherapeutics had a negative net margin of 237.95% and a negative return on equity of 115.86%.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.